{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:40:13Z","timestamp":1789155613392,"version":"build-2803163510"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005760","name":"University of Gothenburg","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005760","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J. Neurovirol."],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Persistent intrathecal immune activation and neuronal injury remain common in people with HIV (PWH) despite effective antiretroviral therapy (ART). We examined longitudinal trajectories of cerebrospinal fluid (CSF) neurofilament light (NfL), a marker of axonal injury, together with neuroinflammatory biomarkers following ART initiation. Ninety-nine PWH from the Gothenburg HIV CSF Study Cohort who achieved viral suppression were included, with CSF samples collected before and after treatment initiation. NfL and a panel of biomarkers including YKL-40, sTREM-2, neopterin, and GFAP were analyzed. CSF NfL declined rapidly, from a mean of 673 ng\/L at baseline to 592 ng\/L after three months and 490 ng\/L after twelve months. All inflammatory biomarkers showed parallel and significant decreases. Prior to ART, 25% of participants had elevated NfL levels; this subgroup displayed higher baseline inflammation, and the steepest biomarker declines after treatment initiation. In participants with normal baseline NfL, inflammatory markers decreased while NfL remained stable. Beyond one year, no further reductions were evident. These longitudinal findings demonstrate that ART rapidly and effectively reduces CSF biomarkers of neuronal injury and neuroinflammation in HIV, with the greatest benefit in individuals with baseline axonal damage.<\/jats:p>","DOI":"10.1007\/s13365-025-01287-2","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T15:13:01Z","timestamp":1761059581000},"page":"574-584","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Rapid decline of cerebrospinal fluid biomarkers of axonal injury and neuroinflammation after initiation of antiretroviral therapy in HIV"],"prefix":"10.1007","volume":"31","author":[{"given":"Linn","family":"Renborg","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aylin","family":"Yilmaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Staffan","family":"Nilsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaj","family":"Blennow","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magnus","family":"Gissl\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"1287_CR1","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1007\/s00415-006-0481-8","volume":"254","author":"S Abdulle","year":"2007","unstructured":"Abdulle S, Mellgren \u00c5, Brew BJ (2007) CSF neurofilament protein (NFL) - a marker of active HIV-related neurodegeneration. J Neurol 254:1026\u20131032. https:\/\/doi.org\/10.1007\/s00415-006-0481-8","journal-title":"J Neurol"},{"key":"1287_CR2","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1007\/s13365-018-0664-y","volume":"24","author":"AM Anderson","year":"2018","unstructured":"Anderson AM, Easley KA, Kasher N et al (2018) Neurofilament light chain in blood is negatively associated with neuropsychological performance in HIV-infected adults and declines with initiation of antiretroviral therapy. J Neurovirol 24:695\u2013701. https:\/\/doi.org\/10.1007\/s13365-018-0664-y","journal-title":"J Neurovirol"},{"key":"1287_CR3","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1097\/QAI.0000000000002484","volume":"85","author":"AM Anderson","year":"2020","unstructured":"Anderson AM, Jang JH, Easley KA et al (2020) Cognitive and neuronal link with inflammation: a longitudinal study in people with and without HIV infection. J Acquir Immune Defic Syndr 85:617\u2013625. https:\/\/doi.org\/10.1097\/QAI.0000000000002484","journal-title":"J Acquir Immune Defic Syndr"},{"key":"1287_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2334-6-141","author":"LM Andersson","year":"2006","unstructured":"Andersson LM, Hagberg L, Rosengren L (2006) Normalisation of cerebrospinal fluid biomarkers parallels improvement of neurological symptoms following HAART in HIV dementia - case report. BMC Infect Dis. https:\/\/doi.org\/10.1186\/1471-2334-6-141","journal-title":"BMC Infect Dis"},{"key":"1287_CR5","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1212\/01.WNL.0000287431.88658.8b","volume":"69","author":"A Antinori","year":"2007","unstructured":"Antinori A, Arendt G, Becker JT et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789\u20131799. https:\/\/doi.org\/10.1212\/01.WNL.0000287431.88658.8b","journal-title":"Neurology"},{"key":"1287_CR6","doi-asserted-by":"publisher","first-page":"882","DOI":"10.1007\/s00415-010-5863-2","volume":"258","author":"M Axelsson","year":"2011","unstructured":"Axelsson M, Malmestr\u00f6m C, Nilsson S (2011) Glial fibrillary acidic protein: a potential biomarker for progression in multiple sclerosis. J Neurol 258:882\u2013888. https:\/\/doi.org\/10.1007\/s00415-010-5863-2","journal-title":"J Neurol"},{"key":"1287_CR7","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1080\/14789450.2017.1304217","volume":"14","author":"F Baldacci","year":"2017","unstructured":"Baldacci F, Lista S, Cavedo E et al (2017) Diagnostic function of the neuroinflammatory biomarker YKL-40 in Alzheimer\u2019s disease and other neurodegenerative diseases. Expert Rev Proteomics 14:285\u2013299. https:\/\/doi.org\/10.1080\/14789450.2017.1304217","journal-title":"Expert Rev Proteomics"},{"key":"1287_CR8","doi-asserted-by":"publisher","first-page":"1189","DOI":"10.3233\/JAD-191254\/SUPPL_FILE\/SJ-PDF-1-ALZ-10.3233_JAD-191254.PDF","volume":"74","author":"G Banerjee","year":"2020","unstructured":"Banerjee G, Ambler G, Keshavan A et al (2020) Cerebrospinal fluid biomarkers in cerebral amyloid angiopathy. J Alzheimer\u2019s Disease 74:1189\u20131201. https:\/\/doi.org\/10.3233\/JAD-191254\/SUPPL_FILE\/SJ-PDF-1-ALZ-10.3233_JAD-191254.PDF","journal-title":"J Alzheimer\u2019s Disease"},{"key":"1287_CR9","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1016\/j.cca.2011.01.022","volume":"412","author":"SE Bojesen","year":"2011","unstructured":"Bojesen SE, Johansen JS, Nordestgaard BG (2011) Plasma YKL-40 levels in healthy subjects from the general population. Clin Chim Acta 412:709\u2013712. https:\/\/doi.org\/10.1016\/j.cca.2011.01.022","journal-title":"Clin Chim Acta"},{"key":"1287_CR10","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofx108","volume":"4","author":"T Booiman","year":"2017","unstructured":"Booiman T, Wit FW, Maurer I et al (2017) High cellular monocyte activation in people living with human immunodeficiency virus on combination antiretroviral therapy and lifestyle-matched controls is associated with greater inflammation in cerebrospinal fluid. Open Forum Infect Dis 4:ofx108. https:\/\/doi.org\/10.1093\/ofid\/ofx108","journal-title":"Open Forum Infect Dis"},{"key":"1287_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1001\/jamaneurol.2019.1534","volume":"76","author":"C Bridel","year":"2019","unstructured":"Bridel C, Van Wieringen WN, Zetterberg H et al (2019) Diagnostic value of cerebrospinal fluid neurofilament light protein in neurology: a systematic review and meta-analysis. JAMA Neurol 76:1035\u20131048. https:\/\/doi.org\/10.1001\/jamaneurol.2019.1534","journal-title":"JAMA Neurol"},{"key":"1287_CR12","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.jneuroim.2016.01.013","volume":"292","author":"J Burman","year":"2016","unstructured":"Burman J, Raininko R, Blennow K (2016) YKL-40 is a CSF biomarker of intrathecal inflammation in secondary progressive multiple sclerosis. J Neuroimmunol 292:52\u201357. https:\/\/doi.org\/10.1016\/j.jneuroim.2016.01.013","journal-title":"J Neuroimmunol"},{"key":"1287_CR13","doi-asserted-by":"publisher","first-page":"3742","DOI":"10.1093\/brain\/awae271","volume":"147","author":"A Calcagno","year":"2024","unstructured":"Calcagno A, Cusato J, Cinque P et al (2024) Serum and CSF biomarkers in asymptomatic patients during primary HIV infection: a randomized study. Brain 147:3742\u20133750. https:\/\/doi.org\/10.1093\/brain\/awae271","journal-title":"Brain"},{"key":"1287_CR14","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1007\/s11904-014-0221-0","volume":"11","author":"P Chan","year":"2014","unstructured":"Chan P, Brew BJ (2014) HIV associated neurocognitive disorders in the modern antiviral treatment era: prevalence, characteristics, biomarkers, and effects of treatment. Curr HIV-AIDS Rep 11:317\u2013324","journal-title":"Curr HIV-AIDS Rep"},{"key":"1287_CR15","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1007\/s00401-021-02296-1","volume":"141","author":"D Diaz-Lucena","year":"2021","unstructured":"Diaz-Lucena D, Kruse N, Th\u00fcne K et al (2021) Trem2 expression in the brain and biological fluids in prion diseases. Acta Neuropathol 141:841\u2013859. https:\/\/doi.org\/10.1007\/s00401-021-02296-1","journal-title":"Acta Neuropathol"},{"key":"1287_CR16","doi-asserted-by":"publisher","first-page":"150","DOI":"10.1016\/0167-5699(88)91203-0","volume":"9","author":"D Fuchs","year":"1988","unstructured":"Fuchs D, Hausen A, Reibnegger G et al (1988) Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today 9:150\u2013155. https:\/\/doi.org\/10.1016\/0167-5699(88)91203-0","journal-title":"Immunol Today"},{"key":"1287_CR17","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1159\/000050753","volume":"46","author":"R Fukuyama","year":"2001","unstructured":"Fukuyama R, Izumoto T, Fushiki S (2001) The cerebrospinal fluid level of glial fibrillary acidic protein is increased in cerebrospinal fluid from Alzheimer\u2019s disease patients and correlates with severity of dementia. Eur Neurol 46:35\u201338. https:\/\/doi.org\/10.1159\/000050753","journal-title":"Eur Neurol"},{"key":"1287_CR18","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0250987","author":"M Gisslen","year":"2021","unstructured":"Gisslen M, Keating SM, Spudich S (2021) Compartmentalization of cerebrospinal fluid inflammation across the spectrum of untreated HIV-1 infection, central nervous system injury and viral suppression. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0250987","journal-title":"PLoS ONE"},{"key":"1287_CR19","doi-asserted-by":"publisher","first-page":"523","DOI":"10.3109\/00365549409011810","volume":"26","author":"M Gissl\u00e9n","year":"1994","unstructured":"Gissl\u00e9n M, Chiodi F, Fuchs D et al (1994) Markers of immune stimulation in the cerebrospinal fluid during HIV infection: a longitudinal study. Scand J Infect Dis 26:523\u2013533. https:\/\/doi.org\/10.3109\/00365549409011810","journal-title":"Scand J Infect Dis"},{"key":"1287_CR20","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1086\/518043","volume":"195","author":"M Gissl\u00e9n","year":"2007","unstructured":"Gissl\u00e9n M, Hagberg L, Brew BJ et al (2007) Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 195:1774\u20131778. https:\/\/doi.org\/10.1086\/518043","journal-title":"J Infect Dis"},{"key":"1287_CR21","doi-asserted-by":"publisher","DOI":"10.1212\/NXI.0000000000000512","volume":"6","author":"M Gissl\u00e9n","year":"2019","unstructured":"Gissl\u00e9n M, Heslegrave A, Veleva E et al (2019) CSF concentrations of soluble TREM2 as a marker of microglial activation in HIV-1 infection. Neurol Neuroimmunol Neuroinflamm 6:e512. https:\/\/doi.org\/10.1212\/NXI.0000000000000512","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"1287_CR22","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1007\/s00415-013-6883-5","volume":"260","author":"A Grahn","year":"2013","unstructured":"Grahn A, Hagberg L, Nilsson S (2013) Cerebrospinal fluid biomarkers in patients with varicella-zoster virus CNS infections. J Neurol 260:1813\u20131821. https:\/\/doi.org\/10.1007\/s00415-013-6883-5","journal-title":"J Neurol"},{"key":"1287_CR23","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2022-070693","volume":"13","author":"L Hagberg","year":"2023","unstructured":"Hagberg L, Gissl\u00e9n M (2023) Cohort profile: a longitudinal study of HIV infection in the central nervous system with focus on cerebrospinal fluid - the Gothenburg HIV CSF study cohort. BMJ Open 13:e070693. https:\/\/doi.org\/10.1136\/bmjopen-2022-070693","journal-title":"BMJ Open"},{"key":"1287_CR24","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1093\/infdis\/168.5.1285","volume":"168","author":"L Hagberg","year":"1993","unstructured":"Hagberg L, Dotevall L, Norkrans G (1993) Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis 168:1285\u20131288. https:\/\/doi.org\/10.1093\/infdis\/168.5.1285","journal-title":"J Infect Dis"},{"key":"1287_CR25","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/S0165-5728(99)00150-2","volume":"102","author":"L Hagberg","year":"2000","unstructured":"Hagberg L, Fuchs D, Rosengren L, Gissl\u00e9n M (2000) Intrathecal immune activation is associated with cerebrospinal fluid markers of neuronal destruction in AIDS patients. J Neuroimmunol 102:51\u201355. https:\/\/doi.org\/10.1016\/S0165-5728(99)00150-2","journal-title":"J Neuroimmunol"},{"key":"1287_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0236162","volume":"15","author":"L Hagberg","year":"2020","unstructured":"Hagberg L, Price RW, Zetterberg H et al (2020) Herpes zoster in HIV-1 infection: the role of CSF pleocytosis in secondary CSF escape and discordance. PLoS ONE 15:e0236162. https:\/\/doi.org\/10.1371\/journal.pone.0236162","journal-title":"PLoS ONE"},{"key":"1287_CR27","doi-asserted-by":"publisher","first-page":"1885","DOI":"10.1093\/infdis\/jiz030","volume":"220","author":"J Hellmuth","year":"2019","unstructured":"Hellmuth J, Slike BM, Sacdalan C et al (2019) Very early initiation of antiretroviral therapy during acute HIV infection is associated with normalized levels of immune activation markers in cerebrospinal fluid but not in plasma. J Infect Dis 220:1885\u20131891. https:\/\/doi.org\/10.1093\/infdis\/jiz030","journal-title":"J Infect Dis"},{"key":"1287_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/s12974-019-1404-9","author":"L Hermansson","year":"2019","unstructured":"Hermansson L, Yilmaz A, Axelsson M et al (2019) Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. J Neuroinflammation. https:\/\/doi.org\/10.1186\/s12974-019-1404-9","journal-title":"J Neuroinflammation"},{"key":"1287_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/S13024-016-0071-X","volume":"11","author":"A Heslegrave","year":"2016","unstructured":"Heslegrave A, Heywood W, Paterson R (2016) Increased cerebrospinal fluid soluble TREM2 concentration in Alzheimer\u2019s disease. Mol Neurodegener 11:3. https:\/\/doi.org\/10.1186\/S13024-016-0071-X","journal-title":"Mol Neurodegener"},{"key":"1287_CR30","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1038\/s41582-018-0058-z","volume":"14","author":"M Khalil","year":"2018","unstructured":"Khalil M, Teunissen CE, Otto M et al (2018) Neurofilaments as biomarkers in neurological disorders. Nat Rev Neurol 14:577\u2013589. https:\/\/doi.org\/10.1038\/s41582-018-0058-z","journal-title":"Nat Rev Neurol"},{"key":"1287_CR31","doi-asserted-by":"publisher","first-page":"1349","DOI":"10.2169\/internalmedicine.47.0893","volume":"47","author":"S Kishida","year":"2008","unstructured":"Kishida S, Ajisawa A (2008) Probable cerebral Mycobacterium avium complex-related immune reconstitution inflammatory syndrome in an HIV-infected patient. Intern Med 47:1349\u20131354. https:\/\/doi.org\/10.2169\/internalmedicine.47.0893","journal-title":"Intern Med"},{"key":"1287_CR32","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0088591","author":"JJ Krut","year":"2014","unstructured":"Krut JJ, Mellberg T, Price RW (2014) Biomarker evidence of axonal injury in neuroasymptomatic HIV-1 patients. PLoS ONE. https:\/\/doi.org\/10.1371\/journal.pone.0088591","journal-title":"PLoS ONE"},{"key":"1287_CR33","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.jmii.2011.12.033","volume":"46","author":"Y-C Lee","year":"2013","unstructured":"Lee Y-C, Lu C-L, Lai C-C et al (2013) Mycobacterium avium complex infection-related immune reconstitution inflammatory syndrome of the central nervous system in an HIV-infected patient: case report and review. J Microbiol Immunol Infect 46:68\u201372. https:\/\/doi.org\/10.1016\/j.jmii.2011.12.033","journal-title":"J Microbiol Immunol Infect"},{"issue":"2","key":"1287_CR34","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1093\/cid\/ciq041","volume":"52","author":"F-X Lescure","year":"2011","unstructured":"Lescure F-X, Omland LH, Engsig FN et al (2011) Incidence and impact on mortality of severe neurocognitive disorders in persons with and without HIV infection: a Danish nationwide cohort study. Clin Infect Dis 52(2):235\u2013243. https:\/\/doi.org\/10.1093\/cid\/ciq041","journal-title":"Clin Infect Dis"},{"key":"1287_CR35","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1038\/nature21029","volume":"541","author":"SA Liddelow","year":"2017","unstructured":"Liddelow SA, Guttenplan KA, Clarke LE (2017) Neurotoxic reactive astrocytes are induced by activated microglia. Nature 541:481\u2013487. https:\/\/doi.org\/10.1038\/nature21029","journal-title":"Nature"},{"key":"1287_CR36","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1001\/jamaneurol.2016.6117","volume":"74","author":"N Mattsson","year":"2017","unstructured":"Mattsson N, Andreasson U, Zetterberg H et al (2017) Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol 74:557\u2013566. https:\/\/doi.org\/10.1001\/jamaneurol.2016.6117","journal-title":"JAMA Neurol"},{"key":"1287_CR37","doi-asserted-by":"publisher","first-page":"1536","DOI":"10.1212\/01.WNL.0000277635.05973.55","volume":"69","author":"\u00c5 Mellgren","year":"2007","unstructured":"Mellgren \u00c5, Price RW, Hagberg L et al (2007) Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology 69:1536\u20131541. https:\/\/doi.org\/10.1212\/01.WNL.0000277635.05973.55","journal-title":"Neurology"},{"key":"1287_CR38","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0033606","author":"S Neselius","year":"2012","unstructured":"Neselius S, Brisby H, Theodorsson A et al (2012) Csf-biomarkers in Olympic boxing: diagnosis and effects of repetitive head trauma. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0033606","journal-title":"PLoS ONE"},{"key":"1287_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.jneuroim.2006.11.032","volume":"184","author":"H Neumann","year":"2007","unstructured":"Neumann H, Takahashi K (2007) Essential role of the microglial triggering receptor expressed on myeloid cells-2 (TREM2) for central nervous tissue immune homeostasis. J Neuroimmunol 184:92\u201399. https:\/\/doi.org\/10.1016\/j.jneuroim.2006.11.032","journal-title":"J Neuroimmunol"},{"key":"1287_CR40","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/s41582-023-00813-2","volume":"19","author":"S Nightingale","year":"2023","unstructured":"Nightingale S, Ances B, Cinque P et al (2023) Cognitive impairment in people living with HIV: consensus recommendations for a new approach. Nat Rev Neurol 19:424\u2013433. https:\/\/doi.org\/10.1038\/s41582-023-00813-2","journal-title":"Nat Rev Neurol"},{"key":"1287_CR41","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/QAD.0000000000001314","volume":"31","author":"MJ Peluso","year":"2017","unstructured":"Peluso MJ, Valcour V, Phanuphak N et al (2017) Immediate initiation of cART is associated with lower levels of cerebrospinal fluid YKL-40, a marker of microglial activation, in HIV-1 infection. AIDS 31:247\u2013252. https:\/\/doi.org\/10.1097\/QAD.0000000000001314","journal-title":"AIDS"},{"key":"1287_CR42","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.jim.2009.09.014","volume":"352","author":"A Petzold","year":"2010","unstructured":"Petzold A, Altintas A, Andreoni L (2010) Neurofilament ELISA validation. J Immunol Methods 352:23\u201331. https:\/\/doi.org\/10.1016\/j.jim.2009.09.014","journal-title":"J Immunol Methods"},{"key":"1287_CR43","doi-asserted-by":"publisher","first-page":"3081","DOI":"10.1093\/brain\/awn217","volume":"131","author":"L Piccio","year":"2008","unstructured":"Piccio L, Buonsanti C, Cella M et al (2008) Identification of soluble TREM-2 in the cerebrospinal fluid and its association with multiple sclerosis and CNS inflammation. Brain 131:3081\u20133091. https:\/\/doi.org\/10.1093\/brain\/awn217","journal-title":"Brain"},{"key":"1287_CR44","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13594","author":"E Ripamonti","year":"2022","unstructured":"Ripamonti E, Ed\u00e9n A, Nilsson S (2022) Longitudinal decline of plasma neurofilament light levels after antiretroviral initiation in people living with HIV. J Intern Med. https:\/\/doi.org\/10.1111\/joim.13594","journal-title":"J Intern Med"},{"key":"1287_CR45","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1097\/QAD.0000000000002980","volume":"35","author":"J Robertson","year":"2021","unstructured":"Robertson J, Ed\u00e9n A, Nystr\u00f6m K (2021) Increased immune activation and signs of neuronal injury in HIV-negative people on preexposure prophylaxis. AIDS 35:2129\u20132136. https:\/\/doi.org\/10.1097\/QAD.0000000000002980","journal-title":"AIDS"},{"key":"1287_CR46","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/0165-0270(94)90011-6","volume":"51","author":"LE Rosengren","year":"1994","unstructured":"Rosengren LE, Wikkels\u00f8 C, Hagberg L (1994) A sensitive ELISA for glial fibrillary acidic protein: application in CSF of adults. J Neurosci Methods 51:197\u2013204. https:\/\/doi.org\/10.1016\/0165-0270(94)90011-6","journal-title":"J Neurosci Methods"},{"key":"1287_CR47","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1212\/WNL.0000000000002277","volume":"86","author":"N Sacktor","year":"2016","unstructured":"Sacktor N, Skolasky RL, Seaberg E et al (2016) Prevalence of HIV-associated neurocognitive disorders in the multicenter AIDS cohort study. Neurology 86:334\u2013340. https:\/\/doi.org\/10.1212\/WNL.0000000000002277","journal-title":"Neurology"},{"key":"1287_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s15010-004-3048-6","volume":"32","author":"B Sporer","year":"2004","unstructured":"Sporer B, Missler U, Magerkurth O et al (2004) Evaluation of CSF glial fibrillary acidic protein (GFAP) as a putative marker for HIV-associated dementia. Infection 32:20\u201323. https:\/\/doi.org\/10.1007\/s15010-004-3048-6","journal-title":"Infection"},{"key":"1287_CR49","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","volume":"72","author":"CL Sutphen","year":"2015","unstructured":"Sutphen CL, Jasielec MS, Shah AR et al (2015) Longitudinal cerebrospinal fluid biomarker changes in preclinical Alzheimer disease during middle age. JAMA Neurol 72:1029\u20131042. https:\/\/doi.org\/10.1001\/jamaneurol.2015.1285","journal-title":"JAMA Neurol"},{"key":"1287_CR50","doi-asserted-by":"publisher","first-page":"2171","DOI":"10.1097\/QAD.0000000000001950","volume":"32","author":"G Ulfhammer","year":"2018","unstructured":"Ulfhammer G, Eden A, Mellgren S et al (2018) Persistent central nervous system immune activation following more than 10 years of effective HIV antiretroviral treatment. AIDS 32:2171\u20132178. https:\/\/doi.org\/10.1097\/QAD.0000000000001950","journal-title":"AIDS"},{"key":"1287_CR51","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae555","volume":"231","author":"G Ulfhammer","year":"2025","unstructured":"Ulfhammer G, Yilmaz A, Mellgren \u00c5 (2025) Asymptomatic cerebrospinal fluid HIV-1 escape: incidence and consequences. J Infect Dis 231:e429\u2013e437. https:\/\/doi.org\/10.1093\/infdis\/jiae555","journal-title":"J Infect Dis"},{"key":"1287_CR52","doi-asserted-by":"publisher","DOI":"10.1371\/JOURNAL.PONE.0135886","author":"M V\u00e5gberg","year":"2015","unstructured":"V\u00e5gberg M, Norgren N, Dring A (2015) Levels and age dependency of neurofilament light and glial fibrillary acidic protein in healthy individuals and their relation to the brain parenchymal fraction. PLoS ONE. https:\/\/doi.org\/10.1371\/JOURNAL.PONE.0135886","journal-title":"PLoS ONE"},{"key":"1287_CR53","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1093\/INFDIS\/JIX553","volume":"217","author":"RA Van Zoest","year":"2018","unstructured":"Van Zoest RA, Underwood J, De Francesco D et al (2018) Structural brain abnormalities in successfully treated HIV infection: associations with disease and cerebrospinal fluid biomarkers. J Infect Dis 217:69\u201381. https:\/\/doi.org\/10.1093\/INFDIS\/JIX553","journal-title":"J Infect Dis"},{"key":"1287_CR54","doi-asserted-by":"publisher","first-page":"3182","DOI":"10.1111\/ene.15978","volume":"30","author":"M Veje","year":"2023","unstructured":"Veje M, Gri\u0161ka V, Pakalnien\u0117 J et al (2023) Serum and cerebrospinal fluid brain damage markers neurofilament light and glial fibrillary acidic protein correlate with tick-borne encephalitis disease severity-a multicentre study on Lithuanian and Swedish patients. Eur J Neurol 30:3182\u20133189. https:\/\/doi.org\/10.1111\/ene.15978","journal-title":"Eur J Neurol"},{"key":"1287_CR55","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-024-01506-8","volume":"16","author":"Y Wang","year":"2024","unstructured":"Wang Y, Ye M, Ji Q et al (2024) The longitudinal trajectory of CSF sTREM2: the Alzheimer\u2019s disease neuroimaging initiative. Alzheimers Res Ther 16:138. https:\/\/doi.org\/10.1186\/s13195-024-01506-8","journal-title":"Alzheimers Res Ther"},{"key":"1287_CR56","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.cmi.2020.09.031","volume":"27","author":"G Westman","year":"2021","unstructured":"Westman G, Aurelius E, Ahlm C et al (2021) Cerebrospinal fluid biomarkers of brain injury, inflammation and synaptic autoimmunity predict long-term neurocognitive outcome in herpes simplex encephalitis. Clin Microbiol Infect 27:1131\u20131136. https:\/\/doi.org\/10.1016\/j.cmi.2020.09.031","journal-title":"Clin Microbiol Infect"},{"key":"1287_CR57","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.3233\/JAD-221180","volume":"93","author":"F Yang","year":"2023","unstructured":"Yang F, Yang L, Fang X et al (2023) Increased cerebrospinal fluid levels of soluble triggering receptor expressed on myeloid cells 2 and chitinase-3-like protein 1 in idiopathic normal-pressure hydrocephalus. J Alzheimers Dis 93:1341\u20131354. https:\/\/doi.org\/10.3233\/JAD-221180","journal-title":"J Alzheimers Dis"},{"key":"1287_CR58","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1186\/1742-2094-10-62","volume":"10","author":"A Yilmaz","year":"2013","unstructured":"Yilmaz A, Yiannoutsos CT, Fuchs D et al (2013) Cerebrospinal fluid neopterin decay characteristics after initiation of antiretroviral therapy. J Neuroinflammation 10:62. https:\/\/doi.org\/10.1186\/1742-2094-10-62","journal-title":"J Neuroinflammation"},{"key":"1287_CR59","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1080\/14737159.2017.1341313","volume":"17","author":"A Yilmaz","year":"2017","unstructured":"Yilmaz A, Blennow K, Hagberg L et al (2017) Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls. Expert Rev Mol Diagn 17:761\u2013770. https:\/\/doi.org\/10.1080\/14737159.2017.1341313","journal-title":"Expert Rev Mol Diagn"},{"key":"1287_CR60","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1007\/s11904-014-0255-3","volume":"12","author":"Z Zayyad","year":"2015","unstructured":"Zayyad Z, Spudich S (2015) Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV-AIDS Rep 12:16\u201324","journal-title":"Curr HIV-AIDS Rep"}],"container-title":["Journal of NeuroVirology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-025-01287-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13365-025-01287-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13365-025-01287-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T14:25:46Z","timestamp":1765549546000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13365-025-01287-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":60,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1287"],"URL":"https:\/\/doi.org\/10.1007\/s13365-025-01287-2","relation":{},"ISSN":["1355-0284","1538-2443"],"issn-type":[{"value":"1355-0284","type":"print"},{"value":"1538-2443","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"3 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 September 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 October 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants gave their informed consent, and the study was approved by the Reginal Ethics Review Board in Gothenburg, Sweden (\u00d6588-01), and performed in accordance with the Helsinki Declaration.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"AY has received honoraria for lectures from GSK\/ViiV and Gilead and participated in an advisory board for MSD, outside submitted work.HZ has served at scientific advisory boards and\/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZpath, Amylyx, Annexon, Apellis, Artery Therapeutics, AZTherapies, Cognito Therapeutics, CogRx, Denali, Eisai, Enigma, LabCorp, Merck Sharp & Dohme, Merry Life, Nervgen, Novo Nordisk, Optoceutics, Passage Bio, Pinteon Therapeutics, Prothena, Quanterix, Red Abbey Labs, reMYND, Roche, Samumed, ScandiBio Therapeutics AB, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures sponsored by Alzecure, BioArctic, Biogen, Cellectricon, Fujirebio, LabCorp, Lilly, Novo Nordisk, Oy Medix Biochemica AB, Roche, and WebMD, is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, and is a shareholder of MicThera (outside submitted work).KB has served as a consultant and at advisory boards for Abbvie, AC Immune, ALZPath, AriBio, Beckman-Coulter, BioArctic, Biogen, Eisai, Lilly, Moleac Pte. Ltd, Neurimmune, Novartis, Ono Pharma, Prothena, Quanterix, Roche Diagnostics, Sunbird Bio, Sanofi and Siemens Healthineers; has served at data monitoring committees for Julius Clinical and Novartis; has given lectures, produced educational materials and participated in educational programs for AC Immune, Biogen, Celdara Medical, Eisai and Roche Diagnostics; and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program, outside the work presented in this paper.MG has received research grants from Gilead Sciences and honoraria as speaker, DSMB committee member and\/or scientific advisor from Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline\/ViiV, Janssen-Cilag, MSD, Novocure, Novo Nordic, Pfizer and Sanofi (outside of submitted work). All mentioned engagements have concluded and are not ongoing.LR and SN declare no competing interests","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}